Delamanid Resistance: Update and Clinical Management. (10th June 2020)

• Record Type: Journal Article
• Authors: Nguyen, Thi Van Anh; Anthony, Richard M; Cao, Thi Thu Huyen; Bañuls, Anne-Laure; Nguyen, Van Anh Thi; Vu, Dinh Hoa; Nguyen, Nhung Viet; Alffenaar, Jan-Willem C
• Is Part Of: Clinical infectious diseases. Volume 71:Number 12(2020)
• Page Start: 3252
• Page End: 3259
• Publication Date: 2020-06-10
• Subjects: delamanid -- drug resistance -- tuberculosis -- drug susceptibility testing -- pharmacokinetics/pharmacodynamics; Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/ciaa755
• Languages: English
• ISSNs: 1058-4838

Abstract

Abstract: Delamanid, a-first-in-class bicyclic nitroimidazole, was recently approved for multidrug-resistant tuberculosis treatment. Pitted against the hope for improving treatment outcomes is the threat of the rapid resistance emergence. This review provides information on the mechanisms of action, resistance emergence, and drug susceptibility testing (DST) for delamanid. Delamanid resistance has already been reported in both in vitro experiments and clinical settings. Although mutations conferring delamanid resistance have been identified in fbiA, fbiB, fbiC, ddn, and fgd1 genes of Mycobacterium tuberculosis, knowledge about the molecular resistance mechanisms is limited, and there remains no standardized DST method. The rapid acquisition of delamanid resistance emphasizes the need for optimal use of new drugs, the need for drug resistance surveillance, and a comprehensive understanding of drug resistance mechanisms. Further studies are necessary to investigate genetic and phenotypic changes that determine clinically relevant delamanid resistance to help develop a rapid delamanid DST. Abstract : Although delamanid resistance has been reported in both in vitro and clinical Mycobacterium tuberculosis isolates and mutations conferring delamanid resistance have been identified in fbiA, fbiB, fbiC, ddn, and fgd, there remains no standardized drug susceptibility testing method, and knowledge about clinically relevant molecular resistance mechanisms is limited.